Don't forget to register to for ISAC's free webinar which is happening today.
"COVID-19: re-vaccination and variant vaccines"
26 September 2022 at 12.00 GMT / 13.00 BST / 14.00 CET
COVID-19 has affected 620 million people and been the cause of death for more than 6.5 million already. Its activity continues throughout the world with approximately 1,000,000 new cases per day despite the precautions to stop the pandemic.
At the beginning, masks, social distancing and hand hygiene were the main tools used to stop the pandemic and we urgently learned how to diagnose COVID-19 fast and treat it appropriately. Then, effective vaccines against SARS-CoV-2 were developed.
Vaccination against COVID-19 has saved millions of lives so far. But there are many problems implementing worldwide vaccination such as production, distribution, cost and vaccine hesitancy issues. Beyond that, at this stage of the pandemic, the world must decide:
• Do we need booster doses?
• Are original vaccines effective or do we need variant vaccines?
• What are those variant vaccines?
Experts in the field will answer these timely and important questions during the webinar - we hope you can join us.
Participants will be able to download a certificate of attendance during the webinar.
Speakers
In a change to the advertised programme, Dr Sultan Abduljawad (Global Scientific Advisor, BioNTech) will present on mRNA Vaccines.
Re-vaccination in COVID-19
Rafael Araos (Research Professor, Institute of Science and Innovation in Medicine, Universidad del Desarrollo, Chile)
Rafael Araos is a physician scientist trained in internal medicine and infectious diseases. He is interested in understanding the transmission dynamics of infectious diseases and evaluating the impact of health interventions. During the COVID-19 pandemic, his group built up a population-based, electronic cohort that has allowed them to determine COVID-19 vaccine effectiveness in the real-world setting.
Inactivated vaccines
Eric Gao (Medical Affairs Director, Sinocav Biotect Ltd, China)
Yongjun (Eric) Gao is currently the Medical Affairs Director at Sinovac. Prior to that, he was the China lead of epidemiology and health economics at Sanofi Pasteur and the Medical Science team lead at Pfizer vaccine. Before joining the industry, he was the director of the office for public hazards emergency response and the senior medical epidemiologist at China CDC for over 10 years. He is an experienced medical epidemiologist with a demonstrated performance history in public health.
mRNA vaccines
Sultan Abduljawad (Global Scientific Advisor, BioNTech)
Sultan Abduljawad is an Immunologist with a PhD in Clinical Medicine from the University of Oxford, where he developed HIV-1 vaccines. He specialised in cellular immunology and translational studies in infectious disease and oncology and led and collaborated on multiple world-leading clinical studies, from the much publicised HIV-1 remission case ‘the London Patient’ to running one of the first studies to extensively characterise the immuno-phenotype of SARS-CoV-2 and efficacy of COVID-19 vaccines in cancer patients.
Vector vaccines
Bárbara Emoingt Furtado (Associated Medical Director for Vaccine & Immune Therapies, AstraZeneca, UK)
Dr Bárbara Furtado graduated as a medical doctor at the Federal University of Rio de Janeiro, Brazil, having specialised in Pediatrics and Pediatric Onco-Hematology at two prestigious institutions in Rio de Janeiro. She joined the pharmaceutical industry in 2012, and since 2016 she has been dedicated to the area of Medical Affairs for Vaccination. During this period, she has participated in the publication of four articles and a book chapter. She is currently Associate Medical Director International for Vaccines and Immunotherapy at AstraZeneca.
-----------------------------------------------------------------------------------------------
Take advantage of reduced registration rates to attend the 32nd International Congress of Antimicrobial Chemotherapy (ICC) which is being held in Perth, Australia from 27 - 30 November 2022.
| |
Early Bird |
Standard |
| Developed Countries Attendee |
$865.00 |
$1,085.00 |
| Developing Countries Attendee |
$645.00 |
$865.00 |
| Day Attendee |
$435.00 |
$545.00 |
** All fees are in Australian Dollars (AUD)
|
